STARD3 and breast carcinoma: By univariate analysis (Figure 6), comparing survival in the STARD3+ and STARD3− groups, we found no significant difference on overall (p = 0.5), breast cancer-specific (p = 0.89), local relapse-free (p = 0.20), and distant metastasis-free (p = 0.7) survivals.